Jeong Eon Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7198945/publications.pdf Version: 2024-02-01



IFONG FON LEF

#	Article	IF	CITATIONS
1	Effect of mind and body education on quality of life among young breast cancer patients: a randomized controlled trial. Supportive Care in Cancer, 2022, 30, 721-729.	1.0	3
2	Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients. Cancer Research and Treatment, 2022, 54, 827-833.	1.3	2
3	Validation of Korean Version of the COmprehensive Score for financial Toxicity (COST) Among Breast Cancer Survivors. Cancer Research and Treatment, 2022, 54, 834-841.	1.3	9
4	Impact of Skeletal Muscle Loss and Visceral Obesity Measured Using Serial CT on the Prognosis of Operable Breast Cancers in Asian Patients. Korean Journal of Radiology, 2022, 23, 159.	1.5	4
5	Immediate breast reconstruction has no impact on the oncologic outcomes of patients treated with post-mastectomy radiation therapy: a comparative analysis based on propensity score matching. Breast Cancer Research and Treatment, 2022, 192, 101-112.	1.1	1
6	Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience. Cancer Research and Treatment, 2022, , .	1.3	8
7	Histologic analysis according to HER2 gene status in HER2 2 + invasive breast cancer: a study of 280 cases comparing ASCO/CAP 2013 and 2018 guideline recommendations. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 749-758.	1.4	2
8	Abstract P1-08-07: Prediction model of the response of neoadjuvant chemotherapy and long term survival according to multi-omic profiling in cooperation with clinicopathologic features in patients with breast cancer. Cancer Research, 2022, 82, P1-08-07-P1-08-07.	0.4	0
9	Abstract P3-13-08: Fusion analysis including NTRK fusion in breast cancers (BC): From RNASeq data analysis from 629 BC tissue samples. Cancer Research, 2022, 82, P3-13-08-P3-13-08.	0.4	0
10	Abstract P3-12-25: Risk of second primary cancers after curative treatment of breast cancer: A Korean nationwide population-based study. Cancer Research, 2022, 82, P3-12-25-P3-12-25.	0.4	0
11	Measurement of Perfusion Heterogeneity within Tumor Habitats on Magnetic Resonance Imaging and Its Association with Prognosis in Breast Cancer Patients. Cancers, 2022, 14, 1858.	1.7	10
12	Relationship Between Breast and Axillary Pathologic Complete Response According to Clinical Nodal Stage: A Nationwide Study From Korean Breast Cancer Society. Journal of Breast Cancer, 2022, 25, 94.	0.8	4
13	Surgical and Oncologic Outcomes of Robotic and Conventional Nipple-Sparing Mastectomy with Immediate Reconstruction: International Multicenter Pooled Data Analysis. Annals of Surgical Oncology, 2022, 29, 6646-6657.	0.7	22
14	A randomized, prospective, multicenter trial of 3D printing, a patient-specific surgical guide for breast-conserving surgery after neoadjuvant chemotherapy: Comparative evaluation according to the presence or absence of surgical guide Journal of Clinical Oncology, 2022, 40, 576-576.	0.8	2
15	Surgical margin status and survival outcomes of breast cancer patients treated with breast-conserving surgery and whole-breast irradiation after neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 2022, 194, 683-692.	1.1	2
16	Breast radiologic complete response is associated with favorable survival outcomes after neoadjuvant chemotherapy in breast cancer. European Journal of Surgical Oncology, 2021, 47, 232-239.	0.5	7
17	Magnetic Resonance Imaging-Guided Breast Biopsy in Korea: A 10-Year Follow-Up Experience. Journal of Breast Cancer, 2021, 24, 377.	0.8	2
18	Changes in Korean National Healthcare Insurance Policy and Breast Cancer Surgery Trend in Korea. Journal of Korean Medical Science, 2021, 36, e194.	1.1	2

#	Article	IF	CITATIONS
19	Effect of Poloxamer-Based Thermo-Sensitive Sol-Gel Agent on Upper Limb Dysfunction after Axillary Lymph Node Dissection: A Double-Blind Randomized Clinical Trial. Journal of Breast Cancer, 2021, 24, 367.	0.8	3
20	Inhibition of platelet‑derived growth factor receptor synergistically increases the pharmacological effect of tamoxifen in estrogen receptor α positive breast cancer. Oncology Letters, 2021, 21, 294.	0.8	13
21	Validation of the GenesWell BCT Score in Young Asian Women With HR+/HER2â^' Early Breast Cancer. Frontiers in Oncology, 2021, 11, 588728.	1.3	2
22	Inhibition of platelet-derived growth factor C and their receptors additionally increases doxorubicin effects in triple-negative breast cancer cells. European Journal of Pharmacology, 2021, 895, 173868.	1.7	15
23	The efficacy and safety of indocyanine green-hyaluronic acid mixture (LuminoMarkâ,,¢) for localization in patients with non-palpable breast lesions: a multi-center open-label parallel phase-2 clinical trial. BMC Surgery, 2021, 21, 134.	0.6	5
24	Celastrol attenuates the inflammatory response by inhibiting IL‑1β expression in triple‑negative breast cancer cells. Oncology Reports, 2021, 45, .	1.2	17
25	Deep Learning-Based Prediction Model for Breast Cancer Recurrence Using Adjuvant Breast Cancer Cohort in Tertiary Cancer Center Registry. Frontiers in Oncology, 2021, 11, 596364.	1.3	14
26	Favorable prognostic factors of oligometastatic breast cancer: A subset analysis of OLIGO-BC1 Journal of Clinical Oncology, 2021, 39, 1026-1026.	0.8	1
27	Genomic characteristics of breast cancer to predict response of neoadjuvant chemotherapy and long-term prognosis Journal of Clinical Oncology, 2021, 39, 557-557.	0.8	6
28	Entelon® (Vitis vinifera Seed Extract) Prevents Cancer Metastasis via the Downregulation of Interleukin-1 Alpha in Triple-Negative Breast Cancer Cells. Molecules, 2021, 26, 3644.	1.7	7
29	YAP, CTGF and Cyr61 are overexpressed in tamoxifen-resistant breast cancer and induce transcriptional repression of ERα. Journal of Cell Science, 2021, 134, .	1.2	18
30	Validation of the Clinical Treatment Score Post–Five Years in Breast Cancer Patients for Predicting Late Distant Recurrence: A Single-Center Investigation in Korea. Frontiers in Oncology, 2021, 11, 691277.	1.3	4
31	Prediction of pathologic complete response to neoadjuvant chemotherapy using machine learning models in patients with breast cancer. Breast Cancer Research and Treatment, 2021, 189, 747-757.	1.1	10
32	Preoperative diagnosis of BRCA1/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients. Scientific Reports, 2021, 11, 14747.	1.6	1
33	Deep learning from HE slides predicts the clinical benefit from adjuvant chemotherapy in hormone receptor-positive breast cancer patients. Scientific Reports, 2021, 11, 17363.	1.6	7
34	Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution's experience in Korea. Breast Cancer Research and Treatment, 2021, 189, 653-663.	1.1	10
35	Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. Breast, 2021, 59, 327-338.	0.9	31
36	Does chemotherapy or radiotherapy affect the postoperative complication in breast cancer patients who underwent immediate breast reconstruction with tissue expander?. BMC Cancer, 2021, 21, 88.	1.1	8

#	Article	IF	CITATIONS
37	Relation Between Tumor Size and Lymph Node Metastasis According to Subtypes of Breast Cancer. Journal of Breast Cancer, 2021, 24, 75.	0.8	19
38	Elevated Level of Nerve Growth Factor (NGF) in Serum-Derived Exosomes Predicts Poor Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. Cancers, 2021, 13, 5260.	1.7	11
39	ls Sentinel Lymph Node Biopsy for Breast Cancer with Cytology-Proven Axillary Metastasis Safe? A Prospective Single-Arm Study. Journal of Clinical Medicine, 2021, 10, 4754.	1.0	0
40	Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study. Blood Cancer Journal, 2021, 11, 200.	2.8	6
41	Association of the Implant Surface Texture Used in Reconstruction With Breast Cancer Recurrence. JAMA Surgery, 2020, 155, 1132.	2.2	27
42	Isoflavone intake on the risk of overall breast cancer and molecular subtypes in women at high risk for hereditary breast cancer. Breast Cancer Research and Treatment, 2020, 184, 615-626.	1.1	3
43	ANK2 Hypermethylation in Canine Mammary Tumors and Human Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 8697.	1.8	11
44	Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. Nature Communications, 2020, 11, 6175.	5.8	92
45	Application of an open-chamber multi-channel microfluidic device to test chemotherapy drugs. Scientific Reports, 2020, 10, 20343.	1.6	3
46	WNT5A augments cell invasiveness by inducing CXCL8 in HER2-positive breast cancer cells. Cytokine, 2020, 135, 155213.	1.4	9
47	Distribution of tumor subtypes in bilateral breast cancer: Comparison between synchronous and metachronous cancer. Asia-Pacific Journal of Clinical Oncology, 2020, , .	0.7	5
48	Serum Vitamin Levels and Their Relationships with Other Biomarkers in Korean Breast Cancer Patients. Nutrients, 2020, 12, 2831.	1.7	6
49	Impact of Serum Lipid on Breast Cancer Recurrence. Journal of Clinical Medicine, 2020, 9, 2846.	1.0	23
50	Prognostication of a 13-immune-related-gene signature in patients with early triple-negative breast cancer. Breast Cancer Research and Treatment, 2020, 184, 325-334.	1.1	18
51	Dietary Intake and Plasma Levels of Isoflavones Among Breast Cancer Survivors. Current Developments in Nutrition, 2020, 4, nzaa061_118.	0.1	0
52	Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer. Molecular Cancer Research, 2020, 18, 1315-1325.	1.5	8
53	Prognosis of BRCA1/2-negative breast cancer patients with HBOC risk factors compared with sporadic breast cancer patients without HBOC risk factors. Japanese Journal of Clinical Oncology, 2020, 50, 104-113.	0.6	2
54	Aberrant Lymphatic Drainage in the Contralateral Axilla in Patients with Isolated Ipsilateral Breast Tumor Recurrence. Journal of Clinical Medicine, 2020, 9, 1192.	1.0	0

#	Article	IF	CITATIONS
55	Trends in Risk-Reducing Mastectomy and Risk-Reducing Salpingo-Oophorectomy in Korean Carriers of the <i>BRCA1/2</i> Mutation. Journal of Breast Cancer, 2020, 23, 647.	0.8	9
56	Clinicopathologic characteristics of HER2-positive pure mucinous carcinoma of the breast. Journal of Pathology and Translational Medicine, 2020, 54, 95-102.	0.4	19
57	Clinicopathological Features of Patients with the BRCA1 c.5339T>C (p.Leu1780Pro) Variant. Cancer Research and Treatment, 2020, 52, 680-688.	1.3	7
58	Surgical impact on anxiety of patients with breast cancer: 12-month follow-up prospective longitudinal study. Annals of Surgical Treatment and Research, 2020, 98, 215.	0.4	8
59	Is the intraoperative frozen section analysis of sentinel lymph nodes necessary in clinically negative node breast cancer?. Annals of Surgical Treatment and Research, 2020, 99, 251.	0.4	5
60	International retrospective cohort study of locoregional and systemic therapy in oligometastatic breast cancer (OLIGO-BC1) Journal of Clinical Oncology, 2020, 38, 1025-1025.	0.8	1
61	TP53 upregulates α‑smooth muscle actin expression in tamoxifen‑resistant breast cancer cells. Oncology Reports, 2019, 41, 1075-1082.	1.2	7
62	Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer. Frontiers in Oncology, 2019, 9, 667.	1.3	12
63	Clinical Features and Outcomes of Invasive Breast Cancer: Age-Specific Analysis of a Modern Hospital-Based Registry. Journal of Global Oncology, 2019, 5, 1-9.	0.5	13
64	Chemoresistance in the Human Triple-Negative Breast Cancer Cell Line MDA-MB-231 Induced by Doxorubicin Gradient Is Associated with Epigenetic Alterations in Histone Deacetylase. Journal of Oncology, 2019, 2019, 1-12.	0.6	44
65	The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients: a large-scale study of Koreans. Hereditary Cancer in Clinical Practice, 2019, 17, 1.	0.6	13
66	Serum Trace Elements and Their Associations with Breast Cancer Subgroups in Korean Breast Cancer Patients. Nutrients, 2019, 11, 37.	1.7	46
67	Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 2019, 176, 591-596.	1.1	25
68	Insights Into Breast Cancer in the East vs the West. JAMA Oncology, 2019, 5, 1489.	3.4	90
69	Practical approaches to automated digital image analysis of Ki-67 labeling index in 997 breast carcinomas and causes of discordance with visual assessment. PLoS ONE, 2019, 14, e0212309.	1.1	18
70	Nomogram for accurate prediction of breast and axillary pathologic response after neoadjuvant chemotherapy in node positive patients with breast cancer. Annals of Surgical Treatment and Research, 2019, 96, 169.	0.4	22
71	Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort. Breast Cancer Research and Treatment, 2019, 175, 203-215.	1.1	13
72	Radiomics signature on 3T dynamic contrast-enhanced magnetic resonance imaging for estrogen receptor-positive invasive breast cancers. Medicine (United States), 2019, 98, e15871.	0.4	23

#	Article	IF	CITATIONS
73	Adherence to the American Cancer Society Guidelines for Cancer Survivors and Health-Related Quality of Life among Breast Cancer Survivors. Nutrients, 2019, 11, 2924.	1.7	13
74	Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea. Breast Cancer Research and Treatment, 2019, 173, 385-395.	1.1	15
75	A predictive model for high/low risk group according to oncotype DX recurrence score using machine learning. European Journal of Surgical Oncology, 2019, 45, 134-140.	0.5	17
76	A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients. Breast Cancer Research and Treatment, 2019, 173, 255-266.	1.1	96
77	Is the high proportion of young age at breast cancer onset a unique feature of Asian breast cancer?. Breast Cancer Research and Treatment, 2019, 173, 189-199.	1.1	27
78	EGFR is a Therapeutic Target in Hormone Receptor-Positive Breast Cancer. Cellular Physiology and Biochemistry, 2019, 53, 805-819.	1.1	26
79	Oncologic Outcomes of Nipple-Sparing Mastectomy with Immediate Breast Reconstruction in Patients with Tumor-Nipple Distance Less than 2.0 cm. Journal of Breast Cancer, 2019, 22, 613.	0.8	18
80	Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance. Cancer Research and Treatment, 2019, 51, 737-747.	1.3	53
81	Berberine Suppresses Cell Motility Through Downregulation of TGF-β1 in Triple Negative Breast Cancer Cells. Cellular Physiology and Biochemistry, 2018, 45, 795-807.	1.1	47
82	A train the trainer program for healthcare professionals tasked with providing psychosocial support to breast cancer survivors. BMC Cancer, 2018, 18, 45.	1.1	7
83	Oncologic Safety of Gonadotropin-Releasing Hormone Agonist for Ovarian Function Protection During Breast Cancer Chemotherapy. Clinical Breast Cancer, 2018, 18, e1165-e1172.	1.1	1
84	Effect of Body Mass Index on Survival in Breast Cancer Patients According to Subtype, Metabolic Syndrome, and Treatment. Clinical Breast Cancer, 2018, 18, e1141-e1147.	1.1	24
85	Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures. Nature Communications, 2018, 9, 1725.	5.8	122
86	Preoperative Axillary US in Early-Stage Breast Cancer: Potential to Prevent Unnecessary Axillary Lymph Node Dissection. Radiology, 2018, 288, 55-63.	3.6	37
87	Risk Factors Affecting Breast Cancer-related Lymphedema: Serial Body Weight Change During Neoadjuvant Anthracycline Plus Cyclophosphamide Followed by Taxane. Clinical Breast Cancer, 2018, 18, e49-e54.	1.1	18
88	SIDR: simultaneous isolation and parallel sequencing of genomic DNA and total RNA from single cells. Genome Research, 2018, 28, 75-87.	2.4	95
89	Development and validation of the smart management strategy for health assessment tool-short form (SAT-SF) in cancer survivors. Quality of Life Research, 2018, 27, 347-354.	1.5	8
90	Genetic and Clinical Characteristics of Phyllodes Tumors of the Breast. Translational Oncology, 2018, 11, 18-23.	1.7	26

#	Article	lF	CITATIONS
91	Genetic Diagnosis before Surgery has an Impact on Surgical Decision in BRCA Mutation Carriers with Breast Cancer. World Journal of Surgery, 2018, 42, 1384-1390.	0.8	9
92	Formation of size-controllable tumour spheroids using a microfluidic pillar array (μFPA) device. Analyst, The, 2018, 143, 5841-5848.	1.7	16
93	Reclassification of <i>BRCA1</i> and <i>BRCA2</i> variants of uncertain significance: a multifactorial analysis of multicentre prospective cohort. Journal of Medical Genetics, 2018, 55, 794-802.	1.5	25
94	BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer. PLoS ONE, 2018, 13, e0207155.	1.1	12
95	Patterns of Axillary Lymph Node Metastasis in Breast Cancer: A Prospective Single-Center Study. Journal of Breast Cancer, 2018, 21, 447.	0.8	2
96	Use of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Patients with Axillary Node-Positive Breast Cancer in Diagnosis. Journal of Breast Cancer, 2018, 21, 433.	0.8	19
97	Prognostic value of immunohistochemically detected p53 in adjuvant chemotherapyâ€ŧreated triple negative breast cancer. Kaohsiung Journal of Medical Sciences, 2018, 34, 663-672.	0.8	8
98	Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Nature Genetics, 2018, 50, 1399-1411.	9.4	145
99	Only estrogen receptor "positive―is not enough to predict the prognosis of breast cancer. Breast Cancer Research and Treatment, 2018, 172, 627-636.	1.1	10
100	Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy. Breast Cancer Research and Treatment, 2018, 171, 649-656.	1.1	10
101	Preoperative dynamic breast magnetic resonance imaging kinetic features using computer-aided diagnosis: Association with survival outcome and tumor aggressiveness in patients with invasive breast cancer. PLoS ONE, 2018, 13, e0195756.	1.1	19
102	Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort. Breast Cancer Research and Treatment, 2018, 171, 737-745.	1.1	27
103	Which Patients with Left Breast Cancer Should be Candidates for Heart-Sparing Radiotherapy?. Journal of Breast Cancer, 2018, 21, 206.	0.8	8
104	Berberine Suppresses Fibronectin Expression through Inhibition of c-Jun Phosphorylation in Breast Cancer Cells. Journal of Breast Cancer, 2018, 21, 21.	0.8	19
105	Breast Cancer Epidemiology of the Working-Age Female Population Reveals Significant Implications for the South Korean Economy. Journal of Breast Cancer, 2018, 21, 91.	0.8	10
106	Prognostic Validation of the American Joint Committee on Cancer 8th Staging System in 24,014 Korean Patients with Breast Cancer. Journal of Breast Cancer, 2018, 21, 173.	0.8	28
107	Verification of a Western Nomogram for Predicting Oncotype DXâ,,¢ Recurrence Scores in Korean Patients with Breast Cancer. Journal of Breast Cancer, 2018, 21, 222.	0.8	4
108	Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells. Phytomedicine, 2018, 50, 43-49.	2.3	56

#	Article	IF	CITATIONS
109	Radiomics Signature on Magnetic Resonance Imaging: Association with Disease-Free Survival in Patients with Invasive Breast Cancer. Clinical Cancer Research, 2018, 24, 4705-4714.	3.2	181
110	Clinical Characteristics and Prognosis of Pregnancy-Associated Breast Cancer: Poor Survival of Luminal B Subtype. Oncology, 2018, 95, 163-169.	0.9	31
111	Distress and body image due to altered appearance in posttreatment and active treatment of breast cancer patients and in general population controls. Palliative and Supportive Care, 2018, 16, 137-145.	0.6	19
112	Use of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with cytology proven axillary node-positive breast cancer at diagnosis Journal of Clinical Oncology, 2018, 36, e12640-e12640.	0.8	0
113	Who are happy survivors? Physical, psychosocial, and spiritual factors associated with happiness of breast cancer survivors during the transition from cancer patient to survivor. Psycho-Oncology, 2017, 26, 1922-1928.	1.0	27
114	A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2â^' early breast cancer. Scientific Reports, 2017, 7, 45554.	1.6	26
115	MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer. Breast Cancer Research and Treatment, 2017, 164, 41-56.	1.1	51
116	Predictive Factors for Nonsentinel Lymph Node Metastasis in Patients With Positive Sentinel Lymph Nodes After Neoadjuvant Chemotherapy: Nomogram for Predicting Nonsentinel Lymph Node Metastasis. Clinical Breast Cancer, 2017, 17, 550-558.	1.1	18
117	Prognostic value of ABO blood types in young patients with breast cancer; a nationwide study in Korean Breast Cancer Society. Medical Oncology, 2017, 34, 118.	1.2	8
118	Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. Nature Communications, 2017, 8, 15081.	5.8	743
119	Suggestion of BRCA1 c.5339T>C (p.L1780P) variant confer from â€~unknown significance' to â€~Likely pathogenic' based on clinical evidence in Korea. Breast, 2017, 33, 109-116.	0.9	16
120	Background parenchymal enhancement on breast MRI: association with recurrence-free survival in patients with newly diagnosed invasive breast cancer. Breast Cancer Research and Treatment, 2017, 163, 573-586.	1.1	29
121	Different prognosis of young breast cancer patients in their 20s and 30s depending on subtype: a nationwide study from the Korean Breast Cancer Society. Breast Cancer Research and Treatment, 2017, 166, 833-842.	1.1	20
122	Outcome following sentinel lymph node biopsy-guided decisions in breast cancer patients with conversion from positive to negative axillary lymph nodes after neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 2017, 166, 473-480.	1.1	32
123	Prevalence and detection of low-allele-fraction variants in clinical cancer samples. Nature Communications, 2017, 8, 1377.	5.8	137
124	Oncologic Safety of Immediate Breast Reconstruction in Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy: Short-Term Outcomes of a Matched Case–Control Study. Clinical Breast Cancer, 2017, 17, 204-210.	1.1	24
125	Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer. Breast Cancer Research and Treatment, 2017, 161, 95-102.	1.1	28
126	Feasibility and Prognostic Effect of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Cytology-Proven, Node-Positive Breast Cancer. Clinical Breast Cancer, 2017, 17, e19-e29.	1.1	14

#	Article	IF	CITATIONS
127	Clinical outcomes according to molecular subtypes in stage II-III breast cancer patients treated with neoadjuvant chemotherapy followed by surgery and radiotherapy. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 329-336.	0.7	12
128	Development of a Nomogram to Predict N2 or N3 Stage in T1–2 Invasive Breast Cancer Patients with No Palpable Lymphadenopathy. Journal of Breast Cancer, 2017, 20, 270.	0.8	12
129	Comparison of Core Needle Biopsy and Surgical Specimens in Determining Intrinsic Biological Subtypes of Breast Cancer with Immunohistochemistry. Journal of Breast Cancer, 2017, 20, 297.	0.8	31
130	Comparison of the association of mammographic density and clinical factors with ductal carcinoma in situ versus invasive ductal breast cancer in Korean women. BMC Cancer, 2017, 17, 821.	1.1	5
131	Fertility Rates in Young Korean Breast Cancer Patients Treated with Gonadotropin-Releasing Hormone and Chemotherapy. Journal of Breast Cancer, 2017, 20, 91.	0.8	6
132	Fibronectin expression is upregulated by PI-3K/Akt activation in tamoxifen-resistant breast cancer cells. BMB Reports, 2017, 50, 615-620.	1.1	16
133	Oncologic Outcomes after Immediate Breast Reconstruction Following Total Mastectomy in Patients with Breast Cancer: A Matched Case-Control Study. Journal of Breast Cancer, 2017, 20, 74.	0.8	15
134	Dimerization of EGFR and HER2 induces breast cancer cell motility through STAT1-dependent ACTA2 induction. Oncotarget, 2017, 8, 50570-50581.	0.8	33
135	Circulating tumor DNA shows variable clonal response of breast cancer during neoadjuvant chemotherapy. Oncotarget, 2017, 8, 86423-86434.	0.8	14
136	Variations in plasma concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer. Oncotarget, 2017, 8, 100296-100311.	0.8	25
137	Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study. Psychiatry Investigation, 2017, 14, 491.	0.7	2
138	Lymph Node Ratio as a Risk Factor for Locoregional Recurrence in Breast Cancer Patients with 10 or More Axillary Nodes. Journal of Breast Cancer, 2016, 19, 169.	0.8	11
139	Radiologic Findings of Primary Mucinous Cystadenocarcinoma of the Breast: A Report of Two Cases and a Literature Review. Journal of Breast Cancer, 2016, 19, 330.	0.8	11
140	Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer. Cancer Research and Treatment, 2016, 48, 1338-1350.	1.3	56
141	Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea. Cancer Research and Treatment, 2016, 48, 1382-1388.	1.3	10
142	Clinicopathological Features and Prognostic Factors Affecting Survival Outcomes in Isolated Locoregional Recurrence of Breast Cancer: Single-Institutional Series. PLoS ONE, 2016, 11, e0163254.	1.1	6
143	Body Mass Index with Tumor 18F-FDG Uptake Improves Risk Stratification in Patients with Breast Cancer. PLoS ONE, 2016, 11, e0165814.	1.1	7
144	Frequency of <scp>MED</scp> 12 mutations in phyllodes tumors: Inverse correlation with histologic grade. Genes Chromosomes and Cancer, 2016, 55, 495-504.	1.5	24

#	Article	IF	CITATIONS
145	STC-1 expression is upregulated through an Akt/NF-κB-dependent pathway in triple-negative breast cancer cells. Oncology Reports, 2016, 36, 1717-1722.	1.2	14
146	The relationship between nuclear factor (NF)-κB family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment. Scientific Reports, 2016, 6, 31804.	1.6	44
147	Feasibility of Nippleâ€Sparing Mastectomy with Immediate Breast Reconstruction in Breast Cancer Patients with Tumorâ€Nipple Distance Less Than 2.0Âcm. World Journal of Surgery, 2016, 40, 2028-2035.	0.8	21
148	MEK activity controls IL-8 expression in tamoxifen-resistant MCF-7 breast cancer cells. Oncology Reports, 2016, 35, 2398-2404.	1.2	7
149	Breast cancer-specific mortality in small-sized tumor with node-positive breast cancer: a nation-wide study in Korean breast cancer society. Breast Cancer Research and Treatment, 2016, 159, 489-498.	1.1	6
150	Goserelin plus tamoxifen compared to chemotherapy followed by tamoxifen in premenopausal patients with early stage-, lymph node-negative breast cancer of luminal A subtype. Breast, 2016, 30, 111-117.	0.9	4
151	Elevated IL-1β expression induces invasiveness of triple negative breast cancer cells and is suppressed by zerumbone. Chemico-Biological Interactions, 2016, 258, 126-133.	1.7	38
152	Prognostic value of ERBB4 expression in patients with triple negative breast cancer. BMC Cancer, 2016, 16, 138.	1.1	39
153	Limited Supraclavicular Radiation Field in Breast Cancer WithÂ≥ 10 Positive Axillary Lymph Nodes. Clinical Breast Cancer, 2016, 16, e15-e21.	1.1	1
154	Silibinin inhibits triple negative breast cancer cell motility by suppressing TGF-β2 expression. Tumor Biology, 2016, 37, 11397-11407.	0.8	28
155	MEK-dependent IL-8 induction regulates the invasiveness of triple-negative breast cancer cells. Tumor Biology, 2016, 37, 4991-4999.	0.8	30
156	Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-121 signaling pathway. Oncotarget, 2016, 7, 1544-1558.	0.8	43
157	Analysis of <i>BRIP1</i> Variants among Korean Patients with <i>BRCA1/2</i> Mutation-Negative High-Risk Breast Cancer. Cancer Research and Treatment, 2016, 48, 955-961.	1.3	8
158	Importance of surgical role on anxiety of patients with breast cancer: Twelve-month follow-up prospective study Journal of Clinical Oncology, 2016, 34, 195-195.	0.8	0
159	Patientâ€reported assessment of selfâ€management strategies of health in cancer patients: development and validation of the Smart Management Strategy for Health Assessment Tool (SAT). Psycho-Oncology, 2015, 24, 1723-1730.	1.0	24
160	Comparison of Clinicopathological Features and Treatment Results between Invasive Lobular Carcinoma and Ductal Carcinoma of the Breast. Journal of Breast Cancer, 2015, 18, 285.	0.8	12
161	Sentinel Lymph Node Biopsy Alone after Neoadjuvant Chemotherapy in Patients with Initial Cytology-Proven Axillary Node Metastasis. Journal of Breast Cancer, 2015, 18, 22.	0.8	23
162	Proportion and Clinical Outcomes of Postoperative Radiotherapy Omission after Breast-Conserving Surgery in Women with Breast Cancer. Journal of Breast Cancer, 2015, 18, 50.	0.8	5

#	Article	IF	CITATIONS
163	Independent Prognostic Factors for Overall Survival after Salvage Operation for Ipsilateral Breast Tumor Recurrence Following Breast-Conserving Surgery. Journal of Breast Cancer, 2015, 18, 386.	0.8	13
164	Distinguishing Low-Risk Luminal A Breast Cancer Subtypes with Ki-67 and p53 Is More Predictive of Long-Term Survival. PLoS ONE, 2015, 10, e0124658.	1.1	27
165	Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay. Oncotarget, 2015, 6, 24499-24510.	0.8	7
166	Differential effect of EGFR inhibitors on tamoxifen-resistant breast cancer cells. Oncology Reports, 2015, 34, 1613-1619.	1.2	21
167	Prevalence and clinical outcomes of young breast cancer (YBC) patients according to intrinsic breast cancer subtypes: Single institutional experience in Korea. Breast, 2015, 24, 213-217.	0.9	23
168	Lateral neck sentinel lymph node biopsy in papillary thyroid carcinoma, is it really necessary? A randomized, controlled study. Surgery, 2015, 157, 518-525.	1.0	17
169	Clinical Outcomes and Prognostic Factors of Pathologic N3 Breast Cancer Treated With Modern Standard Treatments. Clinical Breast Cancer, 2015, 15, 512-518.	1.1	9
170	Elevated TGF-β1 and -β2 expression accelerates the epithelial to mesenchymal transition in triple-negative breast cancer cells. Cytokine, 2015, 75, 151-158.	1.4	40
171	The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population: recent update of the Korean Hereditary Breast Cancer (KOHBRA) study. Breast Cancer Research and Treatment, 2015, 151, 157-168.	1.1	82
172	Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer. BMC Cancer, 2015, 15, 138.	1.1	119
173	The Value of Ki67 in Very Young Women with Hormone Receptor-Positive Breast Cancer: Retrospective Analysis of 9,321 Korean Women. Annals of Surgical Oncology, 2015, 22, 3481-3488.	0.7	20
174	Induction of fibronectin by HER2 overexpression triggers adhesion and invasion of breast cancer cells. Experimental Cell Research, 2015, 333, 116-126.	1.2	36
175	Prognostic Modeling in Pathologic N1 Breast Cancer Without Elective Nodal Irradiation After Current Standard Systemic Management. Clinical Breast Cancer, 2015, 15, e197-e204.	1.1	6
176	Incidental Findings on Simulation CT Images for Adjuvant Radiotherapy in Breast Cancer Patients. Technology in Cancer Research and Treatment, 2015, 14, 525-529.	0.8	6
177	Scanxiety and quality of life among breast cancer survivors Journal of Clinical Oncology, 2015, 33, e20569-e20569.	0.8	3
178	Comparison of prognosis and specific features according to tumor size in small-sized breast cancer with extensive lymph node involvement Journal of Clinical Oncology, 2015, 33, 81-81.	0.8	3
179	Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer. Oncotarget, 2015, 6, 43731-43742.	0.8	63
180	The Clinical Impact of 21-Gene Recurrence Score on Treatment Decisions for Patients with Hormone Receptor-Positive Early Breast Cancer in Korea. Cancer Research and Treatment, 2015, 47, 208-214.	1.3	23

#	Article	IF	CITATIONS
181	Impact on Survival of Regular Postoperative Surveillance for Patients with Early Breast Cancer. Cancer Research and Treatment, 2015, 47, 765-773.	1.3	4
182	Anticancer effect of silibinin on the xenograft model using MDA-MB-468 breast cancer cells. Annals of Surgical Treatment and Research, 2014, 87, 167.	0.4	18
183	Polyostotic Fibrous Dysplasia Mimicking Multiple Bone Metastases in a Patient with Ductal Carcinomaln Situ. Journal of Breast Cancer, 2014, 17, 83.	0.8	5
184	Breast Cancer Screening Knowledge and Perceived Health Beliefs among Immigrant Women in Korea. Journal of Breast Cancer, 2014, 17, 279.	0.8	13
185	Clinical Significance of the Axillary Arch in Sentinel Lymph Node Biopsy. Journal of Breast Cancer, 2014, 17, 244.	0.8	5
186	Acute skin toxicity in Korean breast cancer patients carrying <i>BRCA</i> mutations. International Journal of Radiation Biology, 2014, 90, 90-94.	1.0	21
187	Invasive Paget disease of the breast: 20 years of experience at a single institution. Human Pathology, 2014, 45, 2480-2487.	1.1	22
188	Excision alone for small size ductal carcinoma in situ of the breast. Breast, 2014, 23, 586-590.	0.9	10
189	Ovarian function preservation with GnRH agonist in young breast cancer patients: Does it impede the effect of adjuvant chemotherapy?. Breast, 2014, 23, 670-675.	0.9	12
190	Genetic anticipation of familial breast cancer with or without BRCA mutation in the Korean population. Cancer Genetics, 2014, 207, 160-163.	0.2	8
191	Protein kinase C-α downregulates estrogen receptor-α by suppressing c-Jun phosphorylation in estrogen receptor-positive breast cancer cells. Oncology Reports, 2014, 31, 1423-1428.	1.2	8
192	Role of secreted type I collagen derived from stromal cells in two breast cancer cell lines. Oncology Letters, 2014, 8, 507-512.	0.8	32
193	Induction of fibronectin in response to epidermal growth factor is suppressed by silibinin through the inhibition of STAT3 in triple negative breast cancer cells. Oncology Reports, 2014, 32, 2230-2236.	1.2	27
194	Zerumbone suppresses EGF-induced CD44 expression through the inhibition of STAT3 in breast cancer cells. Oncology Reports, 2014, 32, 2666-2672.	1.2	25
195	Primary Follicular Lymphoma in a Male Breast: A Case Report. Cancer Research and Treatment, 2014, 46, 104-107.	1.3	7
196	HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients. Breast Cancer Research and Treatment, 2013, 139, 741-750.	1.1	52
197	Analysis of Factors that Influence the Accuracy of Magnetic Resonance Imaging for Predicting Response after Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. Annals of Surgical Oncology, 2013, 20, 2562-2568.	0.7	58
198	Round Block Technique Without Cerclage in Breast-Conserving Surgery. Annals of Surgical Oncology, 2013, 20, 3341-3347.	0.7	5

#	Article	IF	CITATIONS
199	Expression of TWIST1, Snail, Slug, and NF-κB and methylation of the TWIST1 promoter in mammary phyllodes tumor. Tumor Biology, 2013, 34, 445-453.	0.8	11
200	HER-2 overexpression is not associated with increased ipsilateral breast tumor recurrence in DCIS treated with breast-conserving surgery followed by radiotherapy. Breast, 2013, 22, 894-897.	0.9	9
201	Does the reconstruction method influence development of mastectomy flap complications in nipple-sparing mastectomy?. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2013, 66, 1543-1550.	0.5	25
202	Ischaemic time and fat necrosis in breast reconstruction with a free deep inferior epigastric perforator flap. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2013, 66, 174-181.	0.5	39
203	Comparison of morbidity of donor site following pedicled muscle-sparing latissimus dorsi flap versus extended latissimus dorsi flap breast reconstruction. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2013, 66, 640-646.	0.5	56
204	The prevalence of BRCA mutations among familial breast cancer patients in Korea: results of the Korean Hereditary Breast Cancer study. Familial Cancer, 2013, 12, 75-81.	0.9	43
205	Berberine Suppresses TPA-Induced Fibronectin Expression through the Inhibition of VEGF Secretion in Breast Cancer Cells. Cellular Physiology and Biochemistry, 2013, 32, 1541-1550.	1.1	37
206	The Clinical Meaning of Intramammary Lymph Nodes. Oncology, 2013, 84, 1-5.	0.9	13
207	Analysis of the effect of breast magnetic resonance imaging on the outcome in women undergoing breast conservation surgery with radiation therapy. Journal of Surgical Oncology, 2013, 107, 815-821.	0.8	22
208	Silibinin inhibits TPA-induced cell migration and MMP-9 expression in thyroid and breast cancer cells. Oncology Reports, 2013, 29, 1343-1348.	1.2	38
209	Rib-Sparing and Internal Mammary Artery–Preserving Microsurgical Breast Reconstruction with the Free DIEP Flap. Plastic and Reconstructive Surgery, 2013, 131, 327e-334e.	0.7	30
210	Aromatase inhibitor-associated musculoskeletal symptoms: incidence and associated factors. [Chapchi] Journal Taehan Oekwa Hakhoe, 2013, 85, 205.	1.1	15
211	Neoadjuvant human epidermal growth factor receptor-2 targeted therapy in patients with locally advanced breast cancer. [Chapchi] Journal Taehan Oekwa Hakhoe, 2013, 84, 273.	1.1	1
212	Validation of a Web-Based Tool to Predict the Ipsilateral Breast Tumor Recurrence (IBTR! 2.0) after Breast-Conserving Therapy for Korean Patients. Journal of Breast Cancer, 2013, 16, 97.	0.8	5
213	Comparison of the Characteristics of Medullary Breast Carcinoma and Invasive Ductal Carcinoma. Journal of Breast Cancer, 2013, 16, 417.	0.8	37
214	Experience of treatment of patients with granulomatous lobular mastitis. [Chapchi] Journal Taehan Oekwa Hakhoe, 2013, 85, 1.	1.1	39
215	Primary breast lymphoma: a single institution's experience. [Chapchi] Journal Taehan Oekwa Hakhoe, 2013, 84, 267.	1.1	11
216	Tubular Carcinoma of the Breast: Clinicopathologic Features and Survival Outcome Compared with Ductal Carcinoma <i>In Situ</i> . Journal of Breast Cancer, 2013, 16, 404.	0.8	27

#	Article	IF	CITATIONS
217	Association between <i>BRCA</i> Mutation Status, Pathological Findings, and Magnetic Resonance Imaging Features in Patients with Breast Cancer at Risk for the Mutation. Journal of Breast Cancer, 2013, 16, 308.	0.8	24
218	Breast Metastasis from Rhabdomyosarcoma of the Anus in an Adolescent Female. Journal of Breast Cancer, 2013, 16, 345.	0.8	4
219	Prognostic factors for survivals from first relapse in breast cancer patients: analysis of deceased patients. Radiation Oncology Journal, 2013, 31, 222.	0.7	21
220	TPA-induced p21 expression augments G2/M arrest through a p53-independent mechanism in human breast cancer cells. Oncology Reports, 2012, 27, 517-22.	1.2	19
221	Methylation and Immunoexpression of <i>p16^{INK4a}</i> Tumor Suppressor Gene in Primary Breast Cancer Tissue and Their Quantitative <i>p16^{INK4a}</i> Hypermethylation in Plasma by Real-Time PCR. Korean Journal of Pathology, 2012, 46, 554.	1.2	26
222	A functional comparison between the HER2high/HER3 and the HER2low/HER3 dimers on heregulin-l²1-induced MMP-1 and MMP-9 expression in breast cancer cells. Experimental and Molecular Medicine, 2012, 44, 473.	3.2	20
223	Lymph Node Metastasis in Patients with Frozen Section Analyses That Are Negative for Tumors. Oncology, 2012, 83, 31-37.	0.9	2
224	Accuracy of BRCA1/2 mutation prediction models in Korean breast cancer patients. Breast Cancer Research and Treatment, 2012, 134, 1189-1197.	1.1	15
225	The prognostic significance of tumor-associated stroma in invasive breast carcinoma. Tumor Biology, 2012, 33, 1573-1580.	0.8	76
226	Berberine Suppresses the TPA-Induced MMP-1 and MMP-9 Expressions Through the Inhibition of PKC-α in Breast Cancer Cells. Journal of Surgical Research, 2012, 176, e21-e29.	0.8	49
227	Smad7 acts as a negative regulator of the epidermal growth factor (EGF) signaling pathway in breast cancer cells. Cancer Letters, 2012, 314, 147-154.	3.2	22
228	Spectra of BRCA1 and BRCA2 mutations in Korean patients with breast cancer: the importance of whole-gene sequencing. Journal of Human Genetics, 2012, 57, 212-215.	1.1	12
229	Clinicopathologic Risk Factors for the Local Recurrence of Phyllodes Tumors of the Breast. Annals of Surgical Oncology, 2012, 19, 2612-2617.	0.7	114
230	Associations between <i>BRCA</i> Mutations in High-Risk Breast Cancer Patients and Familial Cancers Other than Breast or Ovary. Journal of Breast Cancer, 2012, 15, 283.	0.8	25
231	Development of Novel Breast Cancer Recurrence Prediction Model Using Support Vector Machine. Journal of Breast Cancer, 2012, 15, 230.	0.8	143
232	Occult Breast Cancers Manifesting as Axillary Lymph Node Metastasis in Men: A Two-Case Report. Journal of Breast Cancer, 2012, 15, 359.	0.8	15
233	Adjuvant Chemotherapy and Survival of Elderly Korean Patients with Breast Carcinoma. Journal of Breast Cancer, 2012, 15, 296.	0.8	1
234	Invasive Pleomorphic Lobular Carcinoma of the Breast: Clinicopathologic Characteristics and Prognosis Compared with Invasive Ductal Carcinoma. Journal of Breast Cancer, 2012, 15, 313.	0.8	30

#	Article	IF	CITATIONS
235	Long-Term Outcome of Internal Mammary Lymph Node Detected by Lymphoscintigraphy in Early Breast Cancer. Journal of Breast Cancer, 2012, 15, 98.	0.8	14
236	Small node-negative (T1b-cN0) invasive hormone receptor-positive breast cancers: Is there a subpopulation that might have benefit from adjuvant chemotherapy?. Breast Cancer Research and Treatment, 2012, 133, 247-255.	1.1	4
237	Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: The Korean Hereditary Breast Cancer (KOHBRA) Study. Breast Cancer Research and Treatment, 2012, 133, 1143-1152.	1.1	38
238	Characteristics of double heterozygosity for BRCA1 and BRCA2 germline mutations in Korean breast cancer patients. Breast Cancer Research and Treatment, 2012, 131, 217-222.	1.1	17
239	Comparison between screen-detected and symptomatic breast cancers according to molecular subtypes. Breast Cancer Research and Treatment, 2012, 131, 527-540.	1.1	35
240	Efficacy of an Educational Material on Second Primary Cancer Screening Practice for Cancer Survivors: A Randomized Controlled Trial. PLoS ONE, 2012, 7, e33238.	1.1	7
241	Characteristics of medullary breast carcinoma compared with invasive ductal carcinoma Journal of Clinical Oncology, 2012, 30, 20-20.	0.8	0
242	Results from Over One Year of Follow-Up for Absorbable Mesh Insertion in Partial Mastectomy. Yonsei Medical Journal, 2011, 52, 803.	0.9	10
243	Commentary on: Incidental Breast Cancers Identified in a One-Stop Symptomatic Breast Clinic. Journal of Breast Cancer, 2011, 14, 165.	0.8	0
244	Does Immediate Breast Reconstruction after Mastectomy affect the Initiation of Adjuvant Chemotherapy?. Journal of Breast Cancer, 2011, 14, 322.	0.8	29
245	Invited Commentary on: Can CD44+/CD24- Tumor Stem Cells Be Used to Determine the Extent of Breast Cancer Invasion Following Neoadjuvant Chemotherapy?. Journal of Breast Cancer, 2011, 14, 251.	0.8	3
246	Mucinous Carcinoma of the Breast in Comparison with Invasive Ductal Carcinoma: Clinicopathologic Characteristics and Prognosis. Journal of Breast Cancer, 2011, 14, 308.	0.8	93
247	The 70-Gene Prognostic Signature for Korean Breast Cancer Patients. Journal of Breast Cancer, 2011, 14, 33.	0.8	22
248	Is a Thyroid Follicular Neoplasm a Good Indication for Endoscopic Surgery?. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2011, 21, e148-e151.	0.4	13
249	Effect of berberine on p53 expression by TPA in breast cancer cells. Oncology Reports, 2011, 27, 210-5.	1.2	15
250	Radioguided surgery using an intraoperative PET probe for tumor localization and verification of complete resection in differentiated thyroid cancer: A pilot study. Surgery, 2011, 149, 416-424.	1.0	34
251	lleal metastasis of breast cancer in a patient with a BRCA2 gene mutation: Report of a case. Surgery Today, 2011, 41, 1665-1669.	0.7	5
252	The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients. Breast Cancer Research and Treatment, 2011, 126, 471-478.	1.1	130

#	Article	IF	CITATIONS
253	Cases and Literature Review of Breast Sparganosis. World Journal of Surgery, 2011, 35, 573-579.	0.8	30
254	Is Robotic Surgery Superior to Endoscopic and Open Surgeries in Thyroid Cancer?. World Journal of Surgery, 2011, 35, 779-784.	0.8	103
255	Large Clinical Experience of Primary Angiosarcoma of the Breast in a Single Korean Medical Institute. World Journal of Surgery, 2011, 35, 2417-2421.	0.8	15
256	Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC). Cancer Chemotherapy and Pharmacology, 2011, 68, 753-761.	1.1	27
257	Comparison of calcitriol versus cholecalciferol therapy in addition to oral calcium after total thyroidectomy with central neck lymph node dissection: A prospective randomized study. Head and Neck, 2011, 33, 1265-1271.	0.9	14
258	Knowledge, attitudes, risk perception, and cancer screening behaviors among cancer survivors. Cancer, 2011, 117, 3850-3859.	2.0	32
259	New Endoscopic Thyroidectomy With the Bilateral Areolar Approach. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2011, 21, e219-e224.	0.4	16
260	Implications of Bone-Only Metastases in Breast Cancer: Favorable Preference with Excellent Outcomes of Hormone Receptor Positive Breast Cancer. Cancer Research and Treatment, 2011, 43, 89-95.	1.3	79
261	The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced breast cancer: Comparison with ultrasonography and magnetic resonance imaging. Journal of Surgical Oncology, 2010, 102, 392-397.	0.8	44
262	Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status. Cancer Chemotherapy and Pharmacology, 2010, 66, 507-516.	1.1	31
263	Does pre-operative breast magnetic resonance imaging in addition to mammography and breast ultrasonography change the operative management of breast carcinoma?. Breast Cancer Research and Treatment, 2010, 119, 163-167.	1.1	35
264	A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (â‰ ⊉ Âcm) invasive breast cancer: who might be possible candidates for adjuvant treatment?. Breast Cancer Research and Treatment, 2010, 119, 653-661.	1.1	65
265	12-O-Tetradecanoyl phorbol-13-acetate (TPA)-induced growth arrest is increased by silibinin by the down-regulation of cyclin B1 and cdc2 and the up-regulation of p21 expression in MDA-MB231 human breast cancer cells. Phytomedicine, 2010, 17, 1127-1132.	2.3	22
266	Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival. BMC Cancer, 2010, 10, 507.	1.1	46
267	Characteristics of metastasis in the breast from extramammary malignancies. Journal of Surgical Oncology, 2010, 101, 137-140.	0.8	114
268	The prediction of lymph node metastasis in ductal carcinoma in situ with microinvasion by assessing lymphangiogenesis. Journal of Surgical Oncology, 2010, 102, 225-229.	0.8	16
269	One-step Nucleic Acid Amplification (OSNA): Intraoperative Rapid Molecular Diagnostic Method for the Detection of Sentinel Lymph Node Metastases in Breast Cancer Patients in Korean Cohort. Journal of Breast Cancer, 2010, 13, 366.	0.8	3
270	Biopsychosocial Predictors of the Quality of Life in Breast Cancer Patients. Journal of Breast Cancer, 2010, 13, 219.	0.8	11

#	Article	IF	CITATIONS
271	Characteristics of Invasive Micropapillary Carcinoma of the Breast: In Comparison with Invasive Ductal Carcinoma. Journal of Breast Cancer, 2010, 13, 174.	0.8	2
272	The Change of Practice Patterns of the Hereditary Breast Cancer Management in Korea after the Korean Hereditary Breast Cancer Study. Journal of Breast Cancer, 2010, 13, 418.	0.8	8
273	Pifithrin-α, an Inhibitor of p53 Transactivation, Up-Regulates COX-2 Expression through an MAPK-Dependent Pathway. Pharmacology, 2010, 86, 313-319.	0.9	6
274	The Breast and Ovarian Cancer Risks in Korea Due to Inherited Mutations in BRCA1 and BRCA2: A Preliminary Report. Journal of Breast Cancer, 2009, 12, 92.	0.8	17
275	Silibinin Suppresses TNF-α-Induced MMP-9 Expression in Gastric Cancer Cells through Inhibition of the MAPK Pathway. Molecules, 2009, 14, 4300-4311.	1.7	49
276	Silibinin prevents TPA-induced MMP-9 expression and VEGF secretion by inactivation of the Raf/MEK/ERK pathway in MCF-7 human breast cancer cells. Phytomedicine, 2009, 16, 573-580.	2.3	79
277	EGF-induced MMP-9 expression is mediated by the JAK3/ERK pathway, but not by the JAK3/STAT-3 pathway in a SKBR3 breast cancer cell line. Cellular Signalling, 2009, 21, 892-898.	1.7	82
278	Expression of Bmi-1 protein in tumor tissues is associated with favorable prognosis in breast cancer patients. Breast Cancer Research and Treatment, 2009, 113, 83-93.	1.1	46
279	Silibinin prevents TPA-induced MMP-9 expression by down-regulation of COX-2 in human breast cancer cells. Journal of Ethnopharmacology, 2009, 126, 252-257.	2.0	58
280	Experience with Intracystic Papillary Carcinoma of the Breast at a Single Institute in Korea. Journal of Breast Cancer, 2009, 12, 338.	0.8	2
281	CD24 cross-linking induces apoptosis in, and inhibits migration of, MCF-7 breast cancer cells. BMC Cancer, 2008, 8, 118.	1.1	13
282	Berberine Inhibits Growth of the Breast Cancer Cell Lines MCF-7 and MDA-MB-231. Planta Medica, 2008, 74, 39-42.	0.7	50
283	Berberine Suppresses TNF-α-induced MMP-9 and Cell Invasion through Inhibition of AP-1 Activity in MDA-MB-231 Human Breast Cancer Cells. Molecules, 2008, 13, 2975-2985.	1.7	120
284	Downregulation of the RUNX3 Gene by Promoter Hypermethylation and Hemizygous Deletion in Breast Cancer. Journal of Korean Medical Science, 2007, 22, S24.	1.1	26
285	Analysis of Prognostic Factors and Treatment Modality Changes in Breast Cancer: A Single Institution Study in Korea. Yonsei Medical Journal, 2007, 48, 465.	0.9	5
286	Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer. BMC Cancer, 2006, 6, 92.	1.1	63
287	Neogenin expression may be inversely correlated to the tumorigenicity of human breast cancer. BMC Cancer, 2005, 5, 154.	1.1	29
288	Pix-a enhances the activity of phospholipase C?1 by binding SH3 domain in breast cancer. Journal of Cellular Biochemistry, 2005, 94, 1010-1016.	1.2	9

#	Article	IF	CITATIONS
289	The clinical use of staging bone scan in patients with breast carcinoma. Cancer, 2005, 104, 499-503.	2.0	22
290	A Haplotype Analysis of HER-2 Gene Polymorphisms: Association with Breast Cancer Risk, HER-2 Protein Expression in the Tumor, and Disease Recurrence in Korea. Clinical Cancer Research, 2005, 11, 4775-4778.	3.2	44
291	Divorce after breast cancer diagnosis and its impact on quality of life. Palliative and Supportive Care, 0, , 1-6.	0.6	1